Imatinib mesylate-induced molecular remission of Philadelphia chromosome-positive myelodysplastic syndrome.
Drummond
M W
MW
Lush
C J
CJ
Vickers
M A
MA
Reid
F M
FM
Kaeda
J
J
Holyoake
T L
TL
D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001549:Benzamides; D001854:Bone Marrow Cells / Q000473:pathology; D005260:Female; D016044:Fusion Proteins, bcr-abl / Q000235:genetics; D015972:Gene Expression Regulation, Neoplastic; D006098:Granulocytes / Q000473:pathology / Q000502:physiology; D006801:Humans; D000068877:Imatinib Mesylate; D009190:Myelodysplastic Syndromes / Q000188:drug therapy* / Q000235:genetics*; D010677:Philadelphia Chromosome; D010879:Piperazines / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D012333:RNA, Messenger / Q000235:genetics; D014158:Transcription, Genetic
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D012333:RNA, Messenger; D000068877:Imatinib Mesylate; D016044:Fusion Proteins, bcr-abl